Gooding, Sarah http://orcid.org/0000-0002-1549-7043
Olechnowicz, Sam W. Z. http://orcid.org/0000-0001-7879-7708
Morris, Emma V. http://orcid.org/0000-0003-1230-2586
Armitage, Andrew E. http://orcid.org/0000-0001-5977-6602
Arezes, Joao
Frost, Joe
Repapi, Emmanouela http://orcid.org/0000-0001-8085-0731
Edwards, James R. http://orcid.org/0000-0001-7391-0820
Ashley, Neil
Waugh, Craig
Gray, Nicola
Martinez-Hackert, Erik
Lim, Pei Jin
Pasricha, Sant-Rayn http://orcid.org/0000-0002-5502-0434
Knowles, Helen http://orcid.org/0000-0002-9575-6067
Mead, Adam J. http://orcid.org/0000-0001-8522-1002
Ramasamy, Karthik
Drakesmith, Hal http://orcid.org/0000-0002-8503-6103
Edwards, Claire M. http://orcid.org/0000-0002-1257-5659
Funding for this research was provided by:
Wellcome Trust (102341/Z/13/Z)
Arthritis Research UK (20631, MP/19200)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM121499)
RCUK | Medical Research Council (MR/L006340/1, MR/L006340/1)
Article History
Received: 17 January 2018
Accepted: 30 August 2019
First Online: 4 October 2019
Competing interests
: H.D. is on the advisory team of Kymab Ltd. Since completing this work S.G’s research fellowship (University of Oxford) is funded by Celgene. K.R. has research grants from Celgene, Janssen, Amgen and Takeda. K.R. has received honoraria from or is on the advisory board of Celgene, Janssen, Takeda, Amgen, Abbvie and Sanofi. The other authors declare no competing interests.